Details for Patent: 5,321,008
✉ Email this page to a colleague
| Title: | Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions |
| Abstract: | Methods for treatment of diabetes and other insulin-requiring conditions by administering insulin and a calcitonin with or without amylin, and methods for treatment of hypoglycemic conditions by administering a calcitonin alone or in combination with glucagon and/or an amylin, and related compositions. |
| Inventor(s): | Beaumont; Kevin (San Diego, CA), Young; Andrew A. (San Diego, CA) |
| Assignee: | Amylin Pharmaceuticals, Inc. (San Diego, CA) |
| Filing Date: | Oct 10, 1991 |
| Application Number: | 07/774,411 |
| Claims: | 1. A method of treatment of diabetes mellitus, comprising the step of administering a therapeutically effective amount of an insulin and a calcitonin. 2. The method of claim 1 further comprising administering a therapeutically effective amount of an amylin. 3. The method of claim 1 wherein the ratio of insulin to said calcitonin is effective to achieve improved glycemic control over insulin therapy alone. 4. The method of claim 3 wherein said ratio of insulin to said calcitonin is from about 100:1 to about 1:2. 5. The method of claim 3 wherein said ratio of insulin to said calcitonin is from about 1:1 to about 20:1. 6. The method of claim 3 wherein said ratio of insulin to said calcitonin is about 10:1. 7. A method for the treatment of diabetes mellitus in an insulin-requiring mammal comprising administering to said mammal a therapeutically effective amount of a calcitonin. 8. The method of claim 7 wherein said calcitonin is selected from the group consisting of calcitonins of avian and teleost origin. 9. The method of claim 7 wherein said calcitonin is chicken calcitonin. 10. The method of claim 7 wherein said calcitonin is selected from the group consisting of eel calcitonin and salmon calcitonin. 11. The method of claim 7 wherein said mammal is a human. 12. The method of claim 11 wherein said human has type 1 diabetes mellitus. 13. The method of claim 4 wherein said human has type 2 diabetes mellitus. 14. The method of any of claims 7, 12 or 13 further comprising the step of administering a therapeutically effective amount of an amylin. |
